.Attributes Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin caused boosted progression-free and also overall survival, triggering FDA approval and also a new therapy choice for individuals.